Spero Therapeutics Net Income
| SPRO Stock | USD 2.38 0.01 0.42% |
As of the 13th of February 2026, Spero Therapeutics has the Variance of 7.66, coefficient of variation of (22,819), and Risk Adjusted Performance of 0.0035. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Spero Therapeutics, as well as the relationship between them.
Spero Therapeutics Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 3.0105 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -61.7 M | -64.8 M | |
| Net Loss | -41.8 M | -43.9 M | |
| Net Loss | -61.7 M | -64.8 M | |
| Net Loss | (1.14) | (1.20) | |
| Net Income Per E B T | 0.81 | 0.66 |
Spero | Net Income | Build AI portfolio with Spero Stock |
Evaluating Spero Therapeutics's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Spero Therapeutics's fundamental strength.
Latest Spero Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Spero Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Spero Therapeutics financial statement analysis. It represents the amount of money remaining after all of Spero Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Spero Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Spero Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (68.57 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Spero Net Income Regression Statistics
| Arithmetic Mean | (36,488,428) | |
| Geometric Mean | 28,817,740 | |
| Coefficient Of Variation | (85.48) | |
| Mean Deviation | 26,858,638 | |
| Median | (41,662,000) | |
| Standard Deviation | 31,188,671 | |
| Sample Variance | 972.7T | |
| Range | 112.6M | |
| R-Value | (0.59) | |
| Mean Square Error | 676.9T | |
| R-Squared | 0.35 | |
| Significance | 0.01 | |
| Slope | (3,641,350) | |
| Total Sum of Squares | 15563.7T |
Spero Net Income History
Other Fundumenentals of Spero Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Spero Therapeutics Net Income component correlations
Spero Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Spero Therapeutics is extremely important. It helps to project a fair market value of Spero Stock properly, considering its historical fundamentals such as Net Income. Since Spero Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Spero Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Spero Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could Spero diversify its offerings? Factors like these will boost the valuation of Spero Therapeutics. If investors know Spero will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Spero Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 0.753 | Earnings Share (0.79) | Revenue Per Share | Quarterly Revenue Growth (0.60) | Return On Assets |
Understanding Spero Therapeutics requires distinguishing between market price and book value, where the latter reflects Spero's accounting equity. The concept of intrinsic value - what Spero Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Spero Therapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Spero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Spero Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Spero Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Spero Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Spero Therapeutics.
| 11/15/2025 |
| 02/13/2026 |
If you would invest 0.00 in Spero Therapeutics on November 15, 2025 and sell it all today you would earn a total of 0.00 from holding Spero Therapeutics or generate 0.0% return on investment in Spero Therapeutics over 90 days. Spero Therapeutics is related to or competes with Seres Therapeutics, VistaGen Therapeutics, Actuate Therapeutics, Inovio Pharmaceuticals, Acumen Pharmaceuticals, Seer, and Cognition Therapeutics. Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercial... More
Spero Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Spero Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Spero Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.03) | |||
| Maximum Drawdown | 13.07 | |||
| Value At Risk | (5.04) | |||
| Potential Upside | 3.81 |
Spero Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Spero Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Spero Therapeutics' standard deviation. In reality, there are many statistical measures that can use Spero Therapeutics historical prices to predict the future Spero Therapeutics' volatility.| Risk Adjusted Performance | 0.0035 | |||
| Jensen Alpha | (0.13) | |||
| Total Risk Alpha | (0.26) | |||
| Treynor Ratio | (0.02) |
Spero Therapeutics February 13, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0035 | |||
| Market Risk Adjusted Performance | (0.01) | |||
| Mean Deviation | 2.1 | |||
| Coefficient Of Variation | (22,819) | |||
| Standard Deviation | 2.77 | |||
| Variance | 7.66 | |||
| Information Ratio | (0.03) | |||
| Jensen Alpha | (0.13) | |||
| Total Risk Alpha | (0.26) | |||
| Treynor Ratio | (0.02) | |||
| Maximum Drawdown | 13.07 | |||
| Value At Risk | (5.04) | |||
| Potential Upside | 3.81 | |||
| Skewness | (0.31) | |||
| Kurtosis | 0.7186 |
Spero Therapeutics Backtested Returns
Spero Therapeutics owns Efficiency Ratio (i.e., Sharpe Ratio) of close to zero, which indicates the firm had a close to zero % return per unit of risk over the last 3 months. Spero Therapeutics exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please validate Spero Therapeutics' Variance of 7.66, coefficient of variation of (22,819), and Risk Adjusted Performance of 0.0035 to confirm the risk estimate we provide. The entity has a beta of 1.46, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Spero Therapeutics will likely underperform. At this point, Spero Therapeutics has a negative expected return of -0.0014%. Please make sure to validate Spero Therapeutics' coefficient of variation, maximum drawdown, as well as the relationship between the Maximum Drawdown and rate of daily change , to decide if Spero Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.00 |
No correlation between past and present
Spero Therapeutics has no correlation between past and present. Overlapping area represents the amount of predictability between Spero Therapeutics time series from 15th of November 2025 to 30th of December 2025 and 30th of December 2025 to 13th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Spero Therapeutics price movement. The serial correlation of 0.0 indicates that just 0.0% of current Spero Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.0 | |
| Spearman Rank Test | -0.12 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Spero Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Spero Therapeutics reported net income of (68.57 Million). This is 120.09% lower than that of the Biotechnology sector and 197.89% lower than that of the Health Care industry. The net income for all United States stocks is 112.01% higher than that of the company.
Spero Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Spero Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Spero Therapeutics could also be used in its relative valuation, which is a method of valuing Spero Therapeutics by comparing valuation metrics of similar companies.Spero Therapeutics is currently under evaluation in net income category among its peers.
Spero Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Spero Therapeutics from analyzing Spero Therapeutics' financial statements. These drivers represent accounts that assess Spero Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Spero Therapeutics' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 494.6M | 65.0M | 77.5M | 55.7M | 50.1M | 47.6M | |
| Enterprise Value | 389.4M | (37.4M) | 6.7M | 7.1M | 6.4M | 6.0M |
Spero Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Spero Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Spero Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Spero Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Spero Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Spero Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Spero Therapeutics' value.| Shares | State Street Corp | 2025-06-30 | 153.5 K | Ionic Capital Management Llc | 2025-06-30 | 150 K | Adar1 Capital Management Llc | 2025-06-30 | 143.9 K | Bridgeway Capital Management, Llc | 2025-06-30 | 114.8 K | Citadel Advisors Llc | 2025-06-30 | 103.8 K | Northern Trust Corp | 2025-06-30 | 100.8 K | Susquehanna International Group, Llp | 2025-06-30 | 69.8 K | Xtx Topco Ltd | 2025-06-30 | 34.6 K | Axxcess Wealth Management, Llc | 2025-06-30 | 32.5 K | Pfizer Inc | 2025-06-30 | 2.4 M | Vanguard Group Inc | 2025-06-30 | 2 M |
Spero Fundamentals
| Return On Equity | -0.95 | ||||
| Return On Asset | -0.3 | ||||
| Profit Margin | (1.08) % | ||||
| Operating Margin | (1.35) % | ||||
| Current Valuation | 88.26 M | ||||
| Shares Outstanding | 56.34 M | ||||
| Shares Owned By Insiders | 23.34 % | ||||
| Shares Owned By Institutions | 16.58 % | ||||
| Number Of Shares Shorted | 941.66 K | ||||
| Price To Earning | 81.20 X | ||||
| Price To Book | 5.04 X | ||||
| Price To Sales | 3.29 X | ||||
| Revenue | 47.98 M | ||||
| Gross Profit | (21.16 M) | ||||
| EBITDA | (72.48 M) | ||||
| Net Income | (68.57 M) | ||||
| Cash And Equivalents | 45.4 M | ||||
| Cash Per Share | 1.29 X | ||||
| Total Debt | 4.3 M | ||||
| Debt To Equity | 0.19 % | ||||
| Current Ratio | 3.65 X | ||||
| Book Value Per Share | 0.47 X | ||||
| Cash Flow From Operations | (23.44 M) | ||||
| Short Ratio | 4.03 X | ||||
| Earnings Per Share | (0.79) X | ||||
| Target Price | 4.0 | ||||
| Number Of Employees | 32 | ||||
| Beta | 1.45 | ||||
| Market Capitalization | 133.52 M | ||||
| Total Asset | 110.54 M | ||||
| Retained Earnings | (459.64 M) | ||||
| Working Capital | 58.2 M | ||||
| Current Asset | 7.3 M | ||||
| Current Liabilities | 6.04 M | ||||
| Net Asset | 110.54 M |
About Spero Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Spero Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Spero Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Spero Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Spero Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Spero Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Spero Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Spero Stock
The ability to find closely correlated positions to Spero Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Spero Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Spero Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Spero Therapeutics to buy it.
The correlation of Spero Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Spero Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Spero Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Spero Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out To learn how to invest in Spero Stock, please use our How to Invest in Spero Therapeutics guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Will Biotechnology sector continue expanding? Could Spero diversify its offerings? Factors like these will boost the valuation of Spero Therapeutics. If investors know Spero will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Spero Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 0.753 | Earnings Share (0.79) | Revenue Per Share | Quarterly Revenue Growth (0.60) | Return On Assets |
Understanding Spero Therapeutics requires distinguishing between market price and book value, where the latter reflects Spero's accounting equity. The concept of intrinsic value - what Spero Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Spero Therapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Spero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Spero Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.